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Abstract 
Hip fractures are common in patients with COPD and contemporary outcome data is 
needed.  Patients admitted with a hip fracture to one acute trust (2010-2015) were assessed 
prospectively (UK National Hip Fracture Database audit) and mortality data collected. Of the 
4020 patients, 16.2% had a recorded COPD diagnosis. Mortality was significantly greater in 
patients with COPD compared to non-COPD: 30-days (12.6% vs 7.8%) and 1-year (35.3% vs 
25.3%), both p<0.001 and remained significant after adjustment (aOR at 1 year 1.44 95% CI 
1.18 -1.76).  There is further excess mortality following a hip fracture in those with COPD. 
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Editor - Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of 
osteoporosis1 and hip fracture2, with systematic assessment demonstrating osteoporosis in up 
to 32%1. Fracture is a composite of osteoporosis and other factors such as falling, also 
common in COPD3. Previously, worse outcomes have been demonstrated following hip 
fracture in patients with COPD. However, interpretation is limited due to data that is not 
contemporaneous4,5, poorly generalizable5, with limited follow up6 or where confounders 
could not be comprehensively accounted for4,6.  
 
Using the National Hip Fracture Database (NHFD) dataset7 and additional fields from the 
Nottingham centre, the objective of this study was to investigate short and longer-term 
outcomes following hip fracture in patients with COPD. Patients admitted with a hip fracture 
to Nottingham University Hospitals Trust are prospectively audited as part of the NHFD. All 
patients are managed within the local hip fracture pathway, based on national UK standards8. 
Permission to use the dataset was granted by the Trust’s Clinical Quality Risk and Safety 
team, project number 17-267c. Admission co-morbidities (including COPD); length of stay; 
and mode of anaesthesia (regional (RA) or general (GA) anaesthesia) were collected as was 
chest infection (an audit term used for lower respiratory tract infection including pneumonia). 
The Nottingham Hip Fracture Score (NHFS)9 was calculated where possible and mortality 
was collected via the Office for National Statistics. The records of patients presenting 
between 1/10/2010 and 1/10/2015 were retrieved.  Exclusions were all those <50 years old 
and those presenting with bilateral or peri-prosthetic fractures.  
 
Multivariate logistic regression was used to assess the association of COPD diagnosis with 
mortality following admission (30-day and 1-year) and post-operative complications.  Co-
variates (see table 1 and also “chest infection”) were included if they altered the association 
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with COPD by 5% or more. There was minimal missing data in secondary variables (Table 1) 
and all subjects were included in the final analysis with complete age, gender, comorbidities, 
smoking and functional status. As a sensitivity analysis, the preceding 5-year period (1/10/05 
- 30/09/10) was also analysed.  A further analysis examining the association between 
anaesthetic modality and mortality, limited to patients with a diagnosis of COPD was 
conducted, using the same co-variates with the addition of operation type. 
 
Of the total 4020 subjects, there were 651 (16.2%) cases with a recorded admission diagnosis 
of COPD, Table 1. There were more current smokers, more with polypharmacy and a greater 
use enteral steroids in those with COPD. 94 (14%) of patients with COPD were prescribed 
antiresorptive bone treatment on admission.  
 
Both 30-day (12% vs 7.75%) and 1-year (35% vs 25%) mortality were greater in patients 
with COPD than those without. This remained significant after adjustment for confounding 
variables: adjusted odds ratio (aOR) of 1.69 (95%CI 1.28 to 2.23) and 1.44 (1.19 to 1.76) at 
30-days and 1-year respectively. The aOR over the previous 5 years (3808 cases with similar 
demographics and admission characteristics) was similar, as was the crude mortality. Most 
patients (98.3%) were managed operatively, with no difference in type of operation across 
those with or without COPD.  Of those that received an operation, anaesthetic mode differed: 
38.7% of patients with COPD received a GA compared to 58.9% of those without COPD 
(p<0.001). Amongst those with COPD, after adjustment, no difference was noted in mortality 
with the use of RA compared to GA at 30 days (aOR 0.85, 95%CI 0.49 to 1.5, p=0.561), 
however at one-year, was lower in the RA group (aOR 0.61 95%CI 0.42 to 0.90, p=0.012). 
Length of stay was longer for COPD (median 15vs14 days, p=0.018). Of 3676 patients that 
survived to discharge, 48.7% were discharged on an antiresorptive medication.  
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Amongst patients with COPD, 22.7% developed a chest infection during their admission as 
compared to 10.9% of patients without COPD, (aOR 2.41 (95%CI 1.95 to 2.98, p <0.001). 
Chest infection was associated with an aOR of 2.1 (95%CI 1.3 to 2.2, p<0.001) and 2.3 
(95%CI 1.8 to 2.8, p<0.001) for 30-day and 1-year mortality, respectively. When stratified 
for COPD diagnosis the association between chest infection and mortality became non-
significant in the COPD group for both 30-days and 1-year. 
 
We have demonstrated a marked increase in short- and medium-term mortality for patients 
with an admission diagnosis of COPD presenting with a hip fracture compared to those 
without COPD. Patients with COPD were at greater risk of a chest infection and few 
presented on bone antiresorptives at admission.  Mortality risk for patients with COPD and 
hip fracture has been reported previously. Studies from America5 and Denmark4 have shown 
worse mortality in patients with COPD following hip fracture with up to 40% at 1-year where 
COPD was considered “severe”5. In both cases the mortality figures are limited to patients 
that received surgery, which may have excluded those that were less fit on presentation. The 
data reported are not contemporary, making direct comparison difficult, but demonstrate 
similar mortality suggesting there has been little improvement for those with COPD. The 
finding that the development of a chest infection was more common in patients with COPD is 
consistent with existing reports5,10. Previously, chest infection has been shown to be a 
determinant of mortality following hip fracture10. This finding was repeated in this study; 
however, chest infection was not significantly associated with mortality in those patients with 
COPD. This was an unexpected finding but may reflect limitations of the audit term “chest 
infection” used here. 
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Ongoing debate concerning the optimal mode of anaesthesia for patients with hip fracture 
ensues. In this cohort, fewer patients with COPD received a GA, potentially due to comorbid 
chest disease altering the risk benefit judgement about modality of anaesthesia.  In previous 
studies, little, if any difference in mortality has been observed between the two modalities 
generally11, however, RA has previously been associated with better mortality outcomes 
specifically in patients with COPD5 and a similar finding was repeated here; although not 
apparent until the 1-year point. This temporal dissociation makes it difficult to attribute the 
mortality difference directly to the choice of anaesthetic12. Our data are inconclusive on this 
issue and ongoing randomised controlled trials (e.g. REGAIN13) may provide clarity.  
 
The main limitations of this study were that data were drawn from a single site. COPD 
diagnosis was a record of the presence (or not) of COPD, based on presenting history and 
inpatient notes, without spirometric confirmation. No other COPD severity variables such as 
exacerbation frequency or patient related outcomes were available. 
 
Given the substantial excess mortality associated with COPD, efforts to prevent hip fracture 
in this group deserve to be prioritised. Current NICE osteoporosis guidelines suggest 
assessing fracture risk in all patients with COPD14, though this appears to be rarely recorded 
in practice using the Health Improvement Network database15. In this audit, only 14% of 
patients with COPD admitted with hip fracture were prescribed antiresorptives, seemingly 
low, although difficult to retrospectively calculate the correct proportion who should have 
been. 
 
These results demonstrate the implications of this gap in delivering COPD care, which goes 
beyond antiresorptive treatment and includes management of co-morbid factors that 
 7 
contribute to falls risk; as well as non-pharmacological interventions ranging from smoking 
cessation to dietary changes in order to improve bone health. A holistic approach is needed in 
the management of those with COPD.  
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Table 1 Baseline admission characteristics of patients with and without COPD 
presenting with hip fracture between 1st October 2010 and 1st October 2015 
ADLs, activities of daily living; NHFS, Nottingham hip fracture score, ASA, American Society of 
Anaesthesiologists; AMTS, Abbreviated Mental Test Score; TIA, Transient Ischaemic Attack 
∆ Co-variates tested in multivariate logistic regression models assessing mortality and complications as 
outcomes   
* Calculated from component parts on admission   
Ƚ including hypertension  
 
 
 
 
Baseline admission 
characteristics  
Patients with 
COPD 
N= 651 
Patients without 
COPD 
N=3369 
p-value  
 
Age years median (IQR) ∆     82 (75-87) 84(77-89) <0.001 
Male sex n(%) ∆ 215(33.0) 928(27.6) 0.005 
Current smoking n(%) ∆ 130(20.0) 328(9.7) <0.001 
Co-morbidities n(%) ∆ 
Cardiovascular disease ƚ 
Stroke or TIA 
Diabetes 
Renal disease  
Rheumatoid arthritis  
Parkinson’s disease 
Malignancy  
 
437 (67.1) 
103 (15.8) 
122 (18.7) 
83 (12.8) 
31 (4.8) 
15 (2.3) 
88 (13.5) 
 
2129 (63.2) 
504(14.0) 
524(15.6) 
431 (12.8) 
104 (3.1) 
121 (3.6) 
496 (14.7) 
 
0.056 
0.574 
0.043 
0.976 
0.030 
0.096 
0.425 
Four or more medications n(%) ∆ 406(62.4) 1530(45.4) <0.001 
Enteral steroids n(%) ∆ 70(10.8) 113(3.4) <0.001 
Admitted from own home n(%) ∆ 477(73.3) 2475(73.5) 0.818 
Fully independent of ADLs n(%) 
∆ 
234(35.9) 1410 (41.9) 0.005 
Walking independently n (%) 
Unknown  
392(60.2) 
96 (14.8) 
2015(59.8) 
479 (14.2) 
0.670 
 
AMTS ≤6 n(%) ∆ 
Unknown  
168(25.8) 
30(4.6) 
1101(32.7) 
119(3.5) 
0.002 
 
Haemoglobin of ≤10 g/dL  n(%) 
Unknown n(%) ∆ 
68(10.4) 
2 (0.31) 
349(10.4) 
17 (0.5) 
0.797 
NHFS* of ≥6 (/10)   n(%) 
Unknown 
230 (35.3)  
31 (4.8) 
961 (28.5) 
135 (4.0) 
0.001 
ASA grade of ≥4 n(%) 
Unknown 
159(24.4) 
122 (18.7) 
402 (11.9) 
727(21.6) 
<0.001 
Anti-resorptive treatment prior 
to admission n(%) 
94(14.4) 375(11.1) 0.016 
Type of fracture n(%) 
Intracapsular  
Intertrochanteric 
Subtrochanteric  
Other (e.g. reverse oblique) 
 
387(59.5) 
219(33.6) 
33(5.1) 
12(1.8) 
 
2016(60.0) 
1083(32.2) 
201(6.0) 
63(1.9) 
0.78 
